nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxorubicin—NOS3—atherosclerosis	0.173	0.509	CbGaD
Doxorubicin—NOS2—atherosclerosis	0.167	0.491	CbGaD
Doxorubicin—ABCC3—Ezetimibe—atherosclerosis	0.0482	0.126	CbGbCtD
Doxorubicin—ABCB11—Rosuvastatin—atherosclerosis	0.0417	0.109	CbGbCtD
Doxorubicin—ABCB11—Pravastatin—atherosclerosis	0.0379	0.0988	CbGbCtD
Doxorubicin—ABCC1—Rosuvastatin—atherosclerosis	0.0296	0.0771	CbGbCtD
Doxorubicin—ABCC2—Ezetimibe—atherosclerosis	0.0219	0.0571	CbGbCtD
Doxorubicin—ABCC2—Simvastatin—atherosclerosis	0.0204	0.0531	CbGbCtD
Doxorubicin—ABCC2—Pravastatin—atherosclerosis	0.0199	0.052	CbGbCtD
Doxorubicin—ABCC2—Lovastatin—atherosclerosis	0.0199	0.052	CbGbCtD
Doxorubicin—ABCG2—Rosuvastatin—atherosclerosis	0.0198	0.0516	CbGbCtD
Doxorubicin—ABCG2—Ezetimibe—atherosclerosis	0.0198	0.0516	CbGbCtD
Doxorubicin—ABCG2—Pravastatin—atherosclerosis	0.018	0.047	CbGbCtD
Doxorubicin—CYP2B6—Simvastatin—atherosclerosis	0.013	0.0338	CbGbCtD
Doxorubicin—CYP2D6—Niacin—atherosclerosis	0.00792	0.0206	CbGbCtD
Doxorubicin—ABCB1—Ezetimibe—atherosclerosis	0.00714	0.0186	CbGbCtD
Doxorubicin—NOS3—femoral artery—atherosclerosis	0.00689	0.0977	CbGeAlD
Doxorubicin—ABCB1—Simvastatin—atherosclerosis	0.00664	0.0173	CbGbCtD
Doxorubicin—ABCB1—Lovastatin—atherosclerosis	0.0065	0.0169	CbGbCtD
Doxorubicin—ABCB1—Pravastatin—atherosclerosis	0.0065	0.0169	CbGbCtD
Doxorubicin—NOS3—thoracic aorta—atherosclerosis	0.00641	0.0908	CbGeAlD
Doxorubicin—CYP2D6—Simvastatin—atherosclerosis	0.00626	0.0163	CbGbCtD
Doxorubicin—CYP2D6—Lovastatin—atherosclerosis	0.00612	0.016	CbGbCtD
Doxorubicin—CYP2D6—Pravastatin—atherosclerosis	0.00612	0.016	CbGbCtD
Doxorubicin—NOS1—arteriole—atherosclerosis	0.00549	0.0779	CbGeAlD
Doxorubicin—NOS3—middle cerebral artery—atherosclerosis	0.00474	0.0672	CbGeAlD
Doxorubicin—CYP3A4—Ezetimibe—atherosclerosis	0.00428	0.0112	CbGbCtD
Doxorubicin—CYP3A4—Rosuvastatin—atherosclerosis	0.00428	0.0112	CbGbCtD
Doxorubicin—NOS3—arteriole—atherosclerosis	0.00418	0.0592	CbGeAlD
Doxorubicin—CYP3A4—Simvastatin—atherosclerosis	0.00398	0.0104	CbGbCtD
Doxorubicin—CYP3A4—Pravastatin—atherosclerosis	0.00389	0.0101	CbGbCtD
Doxorubicin—CYP3A4—Lovastatin—atherosclerosis	0.00389	0.0101	CbGbCtD
Doxorubicin—NOS3—tunica intima—atherosclerosis	0.00296	0.042	CbGeAlD
Doxorubicin—NOS1—penis—atherosclerosis	0.00288	0.0409	CbGeAlD
Doxorubicin—NOS3—vein—atherosclerosis	0.00249	0.0353	CbGeAlD
Doxorubicin—NOS3—penis—atherosclerosis	0.00219	0.0311	CbGeAlD
Doxorubicin—NOS3—umbilical vein—atherosclerosis	0.00181	0.0256	CbGeAlD
Doxorubicin—NOS3—hindlimb—atherosclerosis	0.00165	0.0235	CbGeAlD
Doxorubicin—NOS3—appendage—atherosclerosis	0.00142	0.0201	CbGeAlD
Doxorubicin—NOS1—artery—atherosclerosis	0.00133	0.0189	CbGeAlD
Doxorubicin—NOS1—endothelium—atherosclerosis	0.00113	0.016	CbGeAlD
Doxorubicin—NOS1—blood vessel—atherosclerosis	0.00104	0.0147	CbGeAlD
Doxorubicin—NOS3—artery—atherosclerosis	0.00101	0.0144	CbGeAlD
Doxorubicin—NOS3—endothelium—atherosclerosis	0.000857	0.0121	CbGeAlD
Doxorubicin—NOS3—blood vessel—atherosclerosis	0.00079	0.0112	CbGeAlD
Doxorubicin—ABCB8—adipose tissue—atherosclerosis	0.000726	0.0103	CbGeAlD
Doxorubicin—CBR3—adipose tissue—atherosclerosis	0.000699	0.0099	CbGeAlD
Doxorubicin—NDUFS7—connective tissue—atherosclerosis	0.000639	0.00906	CbGeAlD
Doxorubicin—AKR1A1—cardiovascular system—atherosclerosis	0.000612	0.00867	CbGeAlD
Doxorubicin—AURKA—Fluvastatin—Rosuvastatin—atherosclerosis	0.000611	0.248	CbGdCrCtD
Doxorubicin—AURKA—Simvastatin—Pravastatin—atherosclerosis	0.000584	0.238	CbGdCrCtD
Doxorubicin—AURKA—Simvastatin—Lovastatin—atherosclerosis	0.000584	0.238	CbGdCrCtD
Doxorubicin—NDUFS7—cardiovascular system—atherosclerosis	0.000556	0.00788	CbGeAlD
Doxorubicin—AKR1A1—adipose tissue—atherosclerosis	0.00054	0.00765	CbGeAlD
Doxorubicin—NDUFS2—connective tissue—atherosclerosis	0.00053	0.0075	CbGeAlD
Doxorubicin—NDUFS3—connective tissue—atherosclerosis	0.000523	0.00741	CbGeAlD
Doxorubicin—ABCB8—liver—atherosclerosis	0.000509	0.00721	CbGeAlD
Doxorubicin—NDUFS7—adipose tissue—atherosclerosis	0.00049	0.00695	CbGeAlD
Doxorubicin—ABCC6—connective tissue—atherosclerosis	0.000484	0.00686	CbGeAlD
Doxorubicin—NOS1—cardiovascular system—atherosclerosis	0.000464	0.00657	CbGeAlD
Doxorubicin—NDUFS2—cardiovascular system—atherosclerosis	0.000461	0.00653	CbGeAlD
Doxorubicin—YWHAG—connective tissue—atherosclerosis	0.000456	0.00646	CbGeAlD
Doxorubicin—NDUFS3—cardiovascular system—atherosclerosis	0.000455	0.00645	CbGeAlD
Doxorubicin—ABCC6—cardiovascular system—atherosclerosis	0.000421	0.00597	CbGeAlD
Doxorubicin—NDUFS2—adipose tissue—atherosclerosis	0.000406	0.00576	CbGeAlD
Doxorubicin—NOS3—connective tissue—atherosclerosis	0.000405	0.00574	CbGeAlD
Doxorubicin—NDUFS3—adipose tissue—atherosclerosis	0.000401	0.00569	CbGeAlD
Doxorubicin—YWHAG—cardiovascular system—atherosclerosis	0.000397	0.00562	CbGeAlD
Doxorubicin—DHCR7—adipose tissue—atherosclerosis	0.000381	0.0054	CbGeAlD
Doxorubicin—AKR1A1—liver—atherosclerosis	0.000378	0.00536	CbGeAlD
Doxorubicin—ABCC6—adipose tissue—atherosclerosis	0.000372	0.00527	CbGeAlD
Doxorubicin—RALBP1—cardiovascular system—atherosclerosis	0.000358	0.00508	CbGeAlD
Doxorubicin—NOS3—cardiovascular system—atherosclerosis	0.000353	0.005	CbGeAlD
Doxorubicin—YWHAG—adipose tissue—atherosclerosis	0.00035	0.00496	CbGeAlD
Doxorubicin—NDUFS7—liver—atherosclerosis	0.000344	0.00487	CbGeAlD
Doxorubicin—CBR1—cardiovascular system—atherosclerosis	0.000335	0.00474	CbGeAlD
Doxorubicin—AURKA—liver—atherosclerosis	0.00032	0.00453	CbGeAlD
Doxorubicin—RALBP1—adipose tissue—atherosclerosis	0.000316	0.00448	CbGeAlD
Doxorubicin—NQO1—connective tissue—atherosclerosis	0.000308	0.00437	CbGeAlD
Doxorubicin—CBR1—adipose tissue—atherosclerosis	0.000295	0.00418	CbGeAlD
Doxorubicin—AKR1C3—adipose tissue—atherosclerosis	0.000291	0.00413	CbGeAlD
Doxorubicin—NDUFS2—liver—atherosclerosis	0.000285	0.00404	CbGeAlD
Doxorubicin—NDUFS3—liver—atherosclerosis	0.000281	0.00399	CbGeAlD
Doxorubicin—NQO1—cardiovascular system—atherosclerosis	0.000268	0.0038	CbGeAlD
Doxorubicin—DHCR7—liver—atherosclerosis	0.000267	0.00379	CbGeAlD
Doxorubicin—POR—adipose tissue—atherosclerosis	0.000266	0.00377	CbGeAlD
Doxorubicin—ABCC6—liver—atherosclerosis	0.000261	0.00369	CbGeAlD
Doxorubicin—TOP2A—adipose tissue—atherosclerosis	0.000248	0.00351	CbGeAlD
Doxorubicin—YWHAG—liver—atherosclerosis	0.000245	0.00348	CbGeAlD
Doxorubicin—XDH—liver—atherosclerosis	0.000239	0.00339	CbGeAlD
Doxorubicin—NQO1—adipose tissue—atherosclerosis	0.000236	0.00335	CbGeAlD
Doxorubicin—ABCB11—liver—atherosclerosis	0.000234	0.00331	CbGeAlD
Doxorubicin—TOP2A—Fluvastatin—Rosuvastatin—atherosclerosis	0.000233	0.0949	CbGdCrCtD
Doxorubicin—TOP2A—Simvastatin—Pravastatin—atherosclerosis	0.000223	0.0907	CbGdCrCtD
Doxorubicin—TOP2A—Simvastatin—Lovastatin—atherosclerosis	0.000223	0.0907	CbGdCrCtD
Doxorubicin—RALBP1—liver—atherosclerosis	0.000222	0.00314	CbGeAlD
Doxorubicin—NOS3—liver—atherosclerosis	0.000218	0.00309	CbGeAlD
Doxorubicin—CYP1B1—connective tissue—atherosclerosis	0.000216	0.00307	CbGeAlD
Doxorubicin—ABCC3—adipose tissue—atherosclerosis	0.000212	0.00301	CbGeAlD
Doxorubicin—ABCC10—adipose tissue—atherosclerosis	0.000211	0.00299	CbGeAlD
Doxorubicin—CBR1—liver—atherosclerosis	0.000207	0.00293	CbGeAlD
Doxorubicin—AKR1C3—liver—atherosclerosis	0.000204	0.0029	CbGeAlD
Doxorubicin—CYP1B1—cardiovascular system—atherosclerosis	0.000188	0.00267	CbGeAlD
Doxorubicin—POR—liver—atherosclerosis	0.000187	0.00264	CbGeAlD
Doxorubicin—CYP1B1—adipose tissue—atherosclerosis	0.000166	0.00235	CbGeAlD
Doxorubicin—NQO1—liver—atherosclerosis	0.000166	0.00235	CbGeAlD
Doxorubicin—ABCB1—blood vessel—atherosclerosis	0.000155	0.0022	CbGeAlD
Doxorubicin—ABCC1—adipose tissue—atherosclerosis	0.000149	0.00212	CbGeAlD
Doxorubicin—ABCC3—liver—atherosclerosis	0.000149	0.00211	CbGeAlD
Doxorubicin—ABCC10—liver—atherosclerosis	0.000148	0.0021	CbGeAlD
Doxorubicin—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000139	0.00143	CcSEcCtD
Doxorubicin—Anaemia—Ezetimibe—atherosclerosis	0.000139	0.00143	CcSEcCtD
Doxorubicin—Tinnitus—Pravastatin—atherosclerosis	0.000139	0.00143	CcSEcCtD
Doxorubicin—Malaise—Lovastatin—atherosclerosis	0.000138	0.00142	CcSEcCtD
Doxorubicin—Cardiac disorder—Pravastatin—atherosclerosis	0.000138	0.00142	CcSEcCtD
Doxorubicin—Flushing—Pravastatin—atherosclerosis	0.000138	0.00142	CcSEcCtD
Doxorubicin—Muscle spasms—Simvastatin—atherosclerosis	0.000138	0.00142	CcSEcCtD
Doxorubicin—Vertigo—Lovastatin—atherosclerosis	0.000138	0.00142	CcSEcCtD
Doxorubicin—Angiopathy—Niacin—atherosclerosis	0.000137	0.00141	CcSEcCtD
Doxorubicin—Leukopenia—Lovastatin—atherosclerosis	0.000137	0.00141	CcSEcCtD
Doxorubicin—Chills—Niacin—atherosclerosis	0.000136	0.0014	CcSEcCtD
Doxorubicin—Malaise—Ezetimibe—atherosclerosis	0.000135	0.00139	CcSEcCtD
Doxorubicin—Vision blurred—Simvastatin—atherosclerosis	0.000135	0.00139	CcSEcCtD
Doxorubicin—Arrhythmia—Niacin—atherosclerosis	0.000135	0.00139	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000134	0.00138	CcSEcCtD
Doxorubicin—Alopecia—Niacin—atherosclerosis	0.000134	0.00137	CcSEcCtD
Doxorubicin—Chills—Pravastatin—atherosclerosis	0.000133	0.00137	CcSEcCtD
Doxorubicin—Insomnia—Rosuvastatin—atherosclerosis	0.000133	0.00137	CcSEcCtD
Doxorubicin—Ill-defined disorder—Simvastatin—atherosclerosis	0.000133	0.00137	CcSEcCtD
Doxorubicin—Arrhythmia—Pravastatin—atherosclerosis	0.000133	0.00137	CcSEcCtD
Doxorubicin—Palpitations—Ezetimibe—atherosclerosis	0.000133	0.00137	CcSEcCtD
Doxorubicin—Paraesthesia—Rosuvastatin—atherosclerosis	0.000132	0.00136	CcSEcCtD
Doxorubicin—Anaemia—Simvastatin—atherosclerosis	0.000132	0.00136	CcSEcCtD
Doxorubicin—Malnutrition—Niacin—atherosclerosis	0.000132	0.00135	CcSEcCtD
Doxorubicin—Erythema—Niacin—atherosclerosis	0.000132	0.00135	CcSEcCtD
Doxorubicin—Alopecia—Pravastatin—atherosclerosis	0.000131	0.00135	CcSEcCtD
Doxorubicin—Cough—Ezetimibe—atherosclerosis	0.000131	0.00135	CcSEcCtD
Doxorubicin—Myalgia—Lovastatin—atherosclerosis	0.00013	0.00134	CcSEcCtD
Doxorubicin—Arthralgia—Lovastatin—atherosclerosis	0.00013	0.00134	CcSEcCtD
Doxorubicin—Chest pain—Lovastatin—atherosclerosis	0.00013	0.00134	CcSEcCtD
Doxorubicin—Anxiety—Lovastatin—atherosclerosis	0.00013	0.00134	CcSEcCtD
Doxorubicin—Dyspepsia—Rosuvastatin—atherosclerosis	0.00013	0.00134	CcSEcCtD
Doxorubicin—Hypertension—Ezetimibe—atherosclerosis	0.00013	0.00133	CcSEcCtD
Doxorubicin—Flatulence—Niacin—atherosclerosis	0.00013	0.00133	CcSEcCtD
Doxorubicin—CYP2B6—cardiovascular system—atherosclerosis	0.000129	0.00183	CbGeAlD
Doxorubicin—Malaise—Simvastatin—atherosclerosis	0.000129	0.00133	CcSEcCtD
Doxorubicin—Tension—Niacin—atherosclerosis	0.000129	0.00133	CcSEcCtD
Doxorubicin—Discomfort—Lovastatin—atherosclerosis	0.000129	0.00133	CcSEcCtD
Doxorubicin—Vertigo—Simvastatin—atherosclerosis	0.000129	0.00132	CcSEcCtD
Doxorubicin—Leukopenia—Simvastatin—atherosclerosis	0.000128	0.00132	CcSEcCtD
Doxorubicin—Chest pain—Ezetimibe—atherosclerosis	0.000128	0.00132	CcSEcCtD
Doxorubicin—Myalgia—Ezetimibe—atherosclerosis	0.000128	0.00132	CcSEcCtD
Doxorubicin—Arthralgia—Ezetimibe—atherosclerosis	0.000128	0.00132	CcSEcCtD
Doxorubicin—Nervousness—Niacin—atherosclerosis	0.000128	0.00131	CcSEcCtD
Doxorubicin—Flatulence—Pravastatin—atherosclerosis	0.000128	0.00131	CcSEcCtD
Doxorubicin—Dry mouth—Lovastatin—atherosclerosis	0.000128	0.00131	CcSEcCtD
Doxorubicin—Tension—Pravastatin—atherosclerosis	0.000127	0.00131	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000127	0.00131	CcSEcCtD
Doxorubicin—Dysgeusia—Pravastatin—atherosclerosis	0.000127	0.00131	CcSEcCtD
Doxorubicin—Muscle spasms—Niacin—atherosclerosis	0.000126	0.0013	CcSEcCtD
Doxorubicin—Discomfort—Ezetimibe—atherosclerosis	0.000126	0.0013	CcSEcCtD
Doxorubicin—Constipation—Rosuvastatin—atherosclerosis	0.000126	0.0013	CcSEcCtD
Doxorubicin—Pain—Rosuvastatin—atherosclerosis	0.000126	0.0013	CcSEcCtD
Doxorubicin—Confusional state—Lovastatin—atherosclerosis	0.000126	0.0013	CcSEcCtD
Doxorubicin—Nervousness—Pravastatin—atherosclerosis	0.000126	0.00129	CcSEcCtD
Doxorubicin—Dry mouth—Ezetimibe—atherosclerosis	0.000125	0.00129	CcSEcCtD
Doxorubicin—Anaphylactic shock—Lovastatin—atherosclerosis	0.000125	0.00129	CcSEcCtD
Doxorubicin—Muscle spasms—Pravastatin—atherosclerosis	0.000125	0.00128	CcSEcCtD
Doxorubicin—Infection—Lovastatin—atherosclerosis	0.000124	0.00128	CcSEcCtD
Doxorubicin—Vision blurred—Niacin—atherosclerosis	0.000124	0.00128	CcSEcCtD
Doxorubicin—Confusional state—Ezetimibe—atherosclerosis	0.000124	0.00127	CcSEcCtD
Doxorubicin—ABCG2—adipose tissue—atherosclerosis	0.000124	0.00175	CbGeAlD
Doxorubicin—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000123	0.00126	CcSEcCtD
Doxorubicin—Thrombocytopenia—Lovastatin—atherosclerosis	0.000122	0.00126	CcSEcCtD
Doxorubicin—Vision blurred—Pravastatin—atherosclerosis	0.000122	0.00126	CcSEcCtD
Doxorubicin—Chest pain—Simvastatin—atherosclerosis	0.000122	0.00125	CcSEcCtD
Doxorubicin—Arthralgia—Simvastatin—atherosclerosis	0.000122	0.00125	CcSEcCtD
Doxorubicin—Myalgia—Simvastatin—atherosclerosis	0.000122	0.00125	CcSEcCtD
Doxorubicin—Infection—Ezetimibe—atherosclerosis	0.000122	0.00125	CcSEcCtD
Doxorubicin—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000122	0.00125	CcSEcCtD
Doxorubicin—Anxiety—Simvastatin—atherosclerosis	0.000122	0.00125	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000121	0.00124	CcSEcCtD
Doxorubicin—Discomfort—Simvastatin—atherosclerosis	0.00012	0.00124	CcSEcCtD
Doxorubicin—Nervous system disorder—Ezetimibe—atherosclerosis	0.00012	0.00124	CcSEcCtD
Doxorubicin—Ill-defined disorder—Pravastatin—atherosclerosis	0.00012	0.00124	CcSEcCtD
Doxorubicin—Thrombocytopenia—Ezetimibe—atherosclerosis	0.00012	0.00124	CcSEcCtD
Doxorubicin—Anaemia—Pravastatin—atherosclerosis	0.00012	0.00123	CcSEcCtD
Doxorubicin—Anorexia—Lovastatin—atherosclerosis	0.000119	0.00123	CcSEcCtD
Doxorubicin—Skin disorder—Ezetimibe—atherosclerosis	0.000119	0.00123	CcSEcCtD
Doxorubicin—ABCC2—liver—atherosclerosis	0.000119	0.00168	CbGeAlD
Doxorubicin—Vertigo—Niacin—atherosclerosis	0.000118	0.00122	CcSEcCtD
Doxorubicin—Syncope—Niacin—atherosclerosis	0.000118	0.00121	CcSEcCtD
Doxorubicin—Confusional state—Simvastatin—atherosclerosis	0.000118	0.00121	CcSEcCtD
Doxorubicin—Leukopenia—Niacin—atherosclerosis	0.000118	0.00121	CcSEcCtD
Doxorubicin—Urticaria—Rosuvastatin—atherosclerosis	0.000117	0.00121	CcSEcCtD
Doxorubicin—Anaphylactic shock—Simvastatin—atherosclerosis	0.000117	0.0012	CcSEcCtD
Doxorubicin—Oedema—Simvastatin—atherosclerosis	0.000117	0.0012	CcSEcCtD
Doxorubicin—Malaise—Pravastatin—atherosclerosis	0.000117	0.0012	CcSEcCtD
Doxorubicin—Abdominal pain—Rosuvastatin—atherosclerosis	0.000117	0.0012	CcSEcCtD
Doxorubicin—CYP1B1—liver—atherosclerosis	0.000116	0.00165	CbGeAlD
Doxorubicin—Vertigo—Pravastatin—atherosclerosis	0.000116	0.0012	CcSEcCtD
Doxorubicin—Palpitations—Niacin—atherosclerosis	0.000116	0.0012	CcSEcCtD
Doxorubicin—Infection—Simvastatin—atherosclerosis	0.000116	0.0012	CcSEcCtD
Doxorubicin—Leukopenia—Pravastatin—atherosclerosis	0.000116	0.00119	CcSEcCtD
Doxorubicin—Loss of consciousness—Niacin—atherosclerosis	0.000116	0.00119	CcSEcCtD
Doxorubicin—Cough—Niacin—atherosclerosis	0.000115	0.00118	CcSEcCtD
Doxorubicin—Thrombocytopenia—Simvastatin—atherosclerosis	0.000114	0.00118	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000114	0.00117	CcSEcCtD
Doxorubicin—Insomnia—Lovastatin—atherosclerosis	0.000113	0.00116	CcSEcCtD
Doxorubicin—Cough—Pravastatin—atherosclerosis	0.000113	0.00116	CcSEcCtD
Doxorubicin—Paraesthesia—Lovastatin—atherosclerosis	0.000112	0.00115	CcSEcCtD
Doxorubicin—Arthralgia—Niacin—atherosclerosis	0.000112	0.00115	CcSEcCtD
Doxorubicin—Myalgia—Niacin—atherosclerosis	0.000112	0.00115	CcSEcCtD
Doxorubicin—Hypertension—Pravastatin—atherosclerosis	0.000112	0.00115	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000112	0.00115	CcSEcCtD
Doxorubicin—Anorexia—Simvastatin—atherosclerosis	0.000111	0.00115	CcSEcCtD
Doxorubicin—Dyspnoea—Lovastatin—atherosclerosis	0.000111	0.00115	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000111	0.00114	CcSEcCtD
Doxorubicin—Insomnia—Ezetimibe—atherosclerosis	0.000111	0.00114	CcSEcCtD
Doxorubicin—Arthralgia—Pravastatin—atherosclerosis	0.00011	0.00113	CcSEcCtD
Doxorubicin—Chest pain—Pravastatin—atherosclerosis	0.00011	0.00113	CcSEcCtD
Doxorubicin—Myalgia—Pravastatin—atherosclerosis	0.00011	0.00113	CcSEcCtD
Doxorubicin—Paraesthesia—Ezetimibe—atherosclerosis	0.00011	0.00113	CcSEcCtD
Doxorubicin—Dyspepsia—Lovastatin—atherosclerosis	0.00011	0.00113	CcSEcCtD
Doxorubicin—Anxiety—Pravastatin—atherosclerosis	0.00011	0.00113	CcSEcCtD
Doxorubicin—Dry mouth—Niacin—atherosclerosis	0.00011	0.00113	CcSEcCtD
Doxorubicin—Dyspnoea—Ezetimibe—atherosclerosis	0.000109	0.00112	CcSEcCtD
Doxorubicin—Discomfort—Pravastatin—atherosclerosis	0.000109	0.00112	CcSEcCtD
Doxorubicin—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000109	0.00112	CcSEcCtD
Doxorubicin—Decreased appetite—Lovastatin—atherosclerosis	0.000109	0.00112	CcSEcCtD
Doxorubicin—Dyspepsia—Ezetimibe—atherosclerosis	0.000108	0.00111	CcSEcCtD
Doxorubicin—Fatigue—Lovastatin—atherosclerosis	0.000108	0.00111	CcSEcCtD
Doxorubicin—Oedema—Niacin—atherosclerosis	0.000107	0.0011	CcSEcCtD
Doxorubicin—Anaphylactic shock—Niacin—atherosclerosis	0.000107	0.0011	CcSEcCtD
Doxorubicin—Constipation—Lovastatin—atherosclerosis	0.000107	0.0011	CcSEcCtD
Doxorubicin—Pain—Lovastatin—atherosclerosis	0.000107	0.0011	CcSEcCtD
Doxorubicin—Confusional state—Pravastatin—atherosclerosis	0.000107	0.0011	CcSEcCtD
Doxorubicin—Decreased appetite—Ezetimibe—atherosclerosis	0.000107	0.0011	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000107	0.0011	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000106	0.00109	CcSEcCtD
Doxorubicin—Asthenia—Rosuvastatin—atherosclerosis	0.000106	0.00109	CcSEcCtD
Doxorubicin—Insomnia—Simvastatin—atherosclerosis	0.000106	0.00109	CcSEcCtD
Doxorubicin—Oedema—Pravastatin—atherosclerosis	0.000106	0.00109	CcSEcCtD
Doxorubicin—Anaphylactic shock—Pravastatin—atherosclerosis	0.000106	0.00109	CcSEcCtD
Doxorubicin—Fatigue—Ezetimibe—atherosclerosis	0.000106	0.00109	CcSEcCtD
Doxorubicin—Shock—Niacin—atherosclerosis	0.000106	0.00109	CcSEcCtD
Doxorubicin—Infection—Pravastatin—atherosclerosis	0.000105	0.00108	CcSEcCtD
Doxorubicin—Paraesthesia—Simvastatin—atherosclerosis	0.000105	0.00108	CcSEcCtD
Doxorubicin—Pain—Ezetimibe—atherosclerosis	0.000105	0.00108	CcSEcCtD
Doxorubicin—Constipation—Ezetimibe—atherosclerosis	0.000105	0.00108	CcSEcCtD
Doxorubicin—Tachycardia—Niacin—atherosclerosis	0.000105	0.00108	CcSEcCtD
Doxorubicin—ABCC1—liver—atherosclerosis	0.000105	0.00148	CbGeAlD
Doxorubicin—Pruritus—Rosuvastatin—atherosclerosis	0.000104	0.00107	CcSEcCtD
Doxorubicin—Skin disorder—Niacin—atherosclerosis	0.000104	0.00107	CcSEcCtD
Doxorubicin—Dyspnoea—Simvastatin—atherosclerosis	0.000104	0.00107	CcSEcCtD
Doxorubicin—Hyperhidrosis—Niacin—atherosclerosis	0.000104	0.00107	CcSEcCtD
Doxorubicin—Thrombocytopenia—Pravastatin—atherosclerosis	0.000103	0.00106	CcSEcCtD
Doxorubicin—Feeling abnormal—Lovastatin—atherosclerosis	0.000103	0.00106	CcSEcCtD
Doxorubicin—Dyspepsia—Simvastatin—atherosclerosis	0.000103	0.00106	CcSEcCtD
Doxorubicin—Anorexia—Niacin—atherosclerosis	0.000102	0.00105	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000102	0.00105	CcSEcCtD
Doxorubicin—Hyperhidrosis—Pravastatin—atherosclerosis	0.000102	0.00105	CcSEcCtD
Doxorubicin—Decreased appetite—Simvastatin—atherosclerosis	0.000102	0.00105	CcSEcCtD
Doxorubicin—Feeling abnormal—Ezetimibe—atherosclerosis	0.000101	0.00104	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000101	0.00104	CcSEcCtD
Doxorubicin—Diarrhoea—Rosuvastatin—atherosclerosis	0.000101	0.00104	CcSEcCtD
Doxorubicin—Fatigue—Simvastatin—atherosclerosis	0.000101	0.00104	CcSEcCtD
Doxorubicin—Anorexia—Pravastatin—atherosclerosis	0.000101	0.00104	CcSEcCtD
Doxorubicin—Hypotension—Niacin—atherosclerosis	0.0001	0.00103	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.0001	0.00103	CcSEcCtD
Doxorubicin—Constipation—Simvastatin—atherosclerosis	0.0001	0.00103	CcSEcCtD
Doxorubicin—Pain—Simvastatin—atherosclerosis	0.0001	0.00103	CcSEcCtD
Doxorubicin—Urticaria—Lovastatin—atherosclerosis	9.93e-05	0.00102	CcSEcCtD
Doxorubicin—Body temperature increased—Lovastatin—atherosclerosis	9.88e-05	0.00102	CcSEcCtD
Doxorubicin—Abdominal pain—Lovastatin—atherosclerosis	9.88e-05	0.00102	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Niacin—atherosclerosis	9.78e-05	0.00101	CcSEcCtD
Doxorubicin—Dizziness—Rosuvastatin—atherosclerosis	9.75e-05	0.001	CcSEcCtD
Doxorubicin—Urticaria—Ezetimibe—atherosclerosis	9.74e-05	0.001	CcSEcCtD
Doxorubicin—Insomnia—Niacin—atherosclerosis	9.71e-05	0.000999	CcSEcCtD
Doxorubicin—Body temperature increased—Ezetimibe—atherosclerosis	9.69e-05	0.000997	CcSEcCtD
Doxorubicin—Abdominal pain—Ezetimibe—atherosclerosis	9.69e-05	0.000997	CcSEcCtD
Doxorubicin—Paraesthesia—Niacin—atherosclerosis	9.64e-05	0.000992	CcSEcCtD
Doxorubicin—Feeling abnormal—Simvastatin—atherosclerosis	9.63e-05	0.000991	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Pravastatin—atherosclerosis	9.63e-05	0.000991	CcSEcCtD
Doxorubicin—Dyspnoea—Niacin—atherosclerosis	9.57e-05	0.000985	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Simvastatin—atherosclerosis	9.56e-05	0.000984	CcSEcCtD
Doxorubicin—Insomnia—Pravastatin—atherosclerosis	9.56e-05	0.000984	CcSEcCtD
Doxorubicin—Somnolence—Niacin—atherosclerosis	9.54e-05	0.000982	CcSEcCtD
Doxorubicin—Paraesthesia—Pravastatin—atherosclerosis	9.49e-05	0.000977	CcSEcCtD
Doxorubicin—Dyspepsia—Niacin—atherosclerosis	9.45e-05	0.000972	CcSEcCtD
Doxorubicin—Dyspnoea—Pravastatin—atherosclerosis	9.42e-05	0.00097	CcSEcCtD
Doxorubicin—Decreased appetite—Niacin—atherosclerosis	9.33e-05	0.00096	CcSEcCtD
Doxorubicin—Dyspepsia—Pravastatin—atherosclerosis	9.3e-05	0.000957	CcSEcCtD
Doxorubicin—Rash—Rosuvastatin—atherosclerosis	9.3e-05	0.000957	CcSEcCtD
Doxorubicin—Dermatitis—Rosuvastatin—atherosclerosis	9.29e-05	0.000956	CcSEcCtD
Doxorubicin—Urticaria—Simvastatin—atherosclerosis	9.29e-05	0.000956	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Niacin—atherosclerosis	9.27e-05	0.000954	CcSEcCtD
Doxorubicin—Abdominal pain—Simvastatin—atherosclerosis	9.24e-05	0.000951	CcSEcCtD
Doxorubicin—Body temperature increased—Simvastatin—atherosclerosis	9.24e-05	0.000951	CcSEcCtD
Doxorubicin—Headache—Rosuvastatin—atherosclerosis	9.24e-05	0.000951	CcSEcCtD
Doxorubicin—Hypersensitivity—Lovastatin—atherosclerosis	9.21e-05	0.000948	CcSEcCtD
Doxorubicin—Decreased appetite—Pravastatin—atherosclerosis	9.19e-05	0.000946	CcSEcCtD
Doxorubicin—Pain—Niacin—atherosclerosis	9.18e-05	0.000945	CcSEcCtD
Doxorubicin—Fatigue—Pravastatin—atherosclerosis	9.11e-05	0.000938	CcSEcCtD
Doxorubicin—Pain—Pravastatin—atherosclerosis	9.04e-05	0.00093	CcSEcCtD
Doxorubicin—Constipation—Pravastatin—atherosclerosis	9.04e-05	0.00093	CcSEcCtD
Doxorubicin—Hypersensitivity—Ezetimibe—atherosclerosis	9.03e-05	0.000929	CcSEcCtD
Doxorubicin—Asthenia—Lovastatin—atherosclerosis	8.97e-05	0.000923	CcSEcCtD
Doxorubicin—Pruritus—Lovastatin—atherosclerosis	8.84e-05	0.00091	CcSEcCtD
Doxorubicin—Asthenia—Ezetimibe—atherosclerosis	8.8e-05	0.000905	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Niacin—atherosclerosis	8.78e-05	0.000903	CcSEcCtD
Doxorubicin—Nausea—Rosuvastatin—atherosclerosis	8.76e-05	0.000902	CcSEcCtD
Doxorubicin—Feeling abnormal—Pravastatin—atherosclerosis	8.71e-05	0.000896	CcSEcCtD
Doxorubicin—Pruritus—Ezetimibe—atherosclerosis	8.67e-05	0.000893	CcSEcCtD
Doxorubicin—ABCG2—liver—atherosclerosis	8.67e-05	0.00123	CbGeAlD
Doxorubicin—Gastrointestinal pain—Pravastatin—atherosclerosis	8.64e-05	0.000889	CcSEcCtD
Doxorubicin—Hypersensitivity—Simvastatin—atherosclerosis	8.61e-05	0.000886	CcSEcCtD
Doxorubicin—Diarrhoea—Lovastatin—atherosclerosis	8.55e-05	0.00088	CcSEcCtD
Doxorubicin—Urticaria—Niacin—atherosclerosis	8.53e-05	0.000878	CcSEcCtD
Doxorubicin—Abdominal pain—Niacin—atherosclerosis	8.49e-05	0.000873	CcSEcCtD
Doxorubicin—Body temperature increased—Niacin—atherosclerosis	8.49e-05	0.000873	CcSEcCtD
Doxorubicin—Urticaria—Pravastatin—atherosclerosis	8.4e-05	0.000864	CcSEcCtD
Doxorubicin—Asthenia—Simvastatin—atherosclerosis	8.39e-05	0.000863	CcSEcCtD
Doxorubicin—Diarrhoea—Ezetimibe—atherosclerosis	8.39e-05	0.000863	CcSEcCtD
Doxorubicin—Abdominal pain—Pravastatin—atherosclerosis	8.36e-05	0.00086	CcSEcCtD
Doxorubicin—Body temperature increased—Pravastatin—atherosclerosis	8.36e-05	0.00086	CcSEcCtD
Doxorubicin—Pruritus—Simvastatin—atherosclerosis	8.27e-05	0.000851	CcSEcCtD
Doxorubicin—Dizziness—Lovastatin—atherosclerosis	8.27e-05	0.000851	CcSEcCtD
Doxorubicin—Dizziness—Ezetimibe—atherosclerosis	8.11e-05	0.000834	CcSEcCtD
Doxorubicin—Diarrhoea—Simvastatin—atherosclerosis	8e-05	0.000823	CcSEcCtD
Doxorubicin—CYP2B6—liver—atherosclerosis	8e-05	0.00113	CbGeAlD
Doxorubicin—Vomiting—Lovastatin—atherosclerosis	7.95e-05	0.000818	CcSEcCtD
Doxorubicin—Hypersensitivity—Niacin—atherosclerosis	7.91e-05	0.000814	CcSEcCtD
Doxorubicin—Rash—Lovastatin—atherosclerosis	7.88e-05	0.000811	CcSEcCtD
Doxorubicin—Dermatitis—Lovastatin—atherosclerosis	7.87e-05	0.00081	CcSEcCtD
Doxorubicin—Headache—Lovastatin—atherosclerosis	7.83e-05	0.000806	CcSEcCtD
Doxorubicin—Vomiting—Ezetimibe—atherosclerosis	7.79e-05	0.000802	CcSEcCtD
Doxorubicin—Hypersensitivity—Pravastatin—atherosclerosis	7.79e-05	0.000801	CcSEcCtD
Doxorubicin—Dizziness—Simvastatin—atherosclerosis	7.73e-05	0.000796	CcSEcCtD
Doxorubicin—Rash—Ezetimibe—atherosclerosis	7.73e-05	0.000795	CcSEcCtD
Doxorubicin—Dermatitis—Ezetimibe—atherosclerosis	7.72e-05	0.000795	CcSEcCtD
Doxorubicin—Asthenia—Niacin—atherosclerosis	7.7e-05	0.000793	CcSEcCtD
Doxorubicin—Headache—Ezetimibe—atherosclerosis	7.68e-05	0.00079	CcSEcCtD
Doxorubicin—Pruritus—Niacin—atherosclerosis	7.59e-05	0.000782	CcSEcCtD
Doxorubicin—Asthenia—Pravastatin—atherosclerosis	7.58e-05	0.00078	CcSEcCtD
Doxorubicin—Pruritus—Pravastatin—atherosclerosis	7.48e-05	0.00077	CcSEcCtD
Doxorubicin—Vomiting—Simvastatin—atherosclerosis	7.43e-05	0.000765	CcSEcCtD
Doxorubicin—Nausea—Lovastatin—atherosclerosis	7.42e-05	0.000764	CcSEcCtD
Doxorubicin—Rash—Simvastatin—atherosclerosis	7.37e-05	0.000759	CcSEcCtD
Doxorubicin—Dermatitis—Simvastatin—atherosclerosis	7.36e-05	0.000758	CcSEcCtD
Doxorubicin—Diarrhoea—Niacin—atherosclerosis	7.34e-05	0.000756	CcSEcCtD
Doxorubicin—Headache—Simvastatin—atherosclerosis	7.32e-05	0.000754	CcSEcCtD
Doxorubicin—Nausea—Ezetimibe—atherosclerosis	7.28e-05	0.000749	CcSEcCtD
Doxorubicin—Diarrhoea—Pravastatin—atherosclerosis	7.23e-05	0.000744	CcSEcCtD
Doxorubicin—Dizziness—Niacin—atherosclerosis	7.1e-05	0.00073	CcSEcCtD
Doxorubicin—Dizziness—Pravastatin—atherosclerosis	6.99e-05	0.000719	CcSEcCtD
Doxorubicin—Nausea—Simvastatin—atherosclerosis	6.94e-05	0.000715	CcSEcCtD
Doxorubicin—ABCB1—cardiovascular system—atherosclerosis	6.91e-05	0.000979	CbGeAlD
Doxorubicin—Vomiting—Niacin—atherosclerosis	6.83e-05	0.000702	CcSEcCtD
Doxorubicin—Rash—Niacin—atherosclerosis	6.77e-05	0.000697	CcSEcCtD
Doxorubicin—Dermatitis—Niacin—atherosclerosis	6.76e-05	0.000696	CcSEcCtD
Doxorubicin—Headache—Niacin—atherosclerosis	6.73e-05	0.000692	CcSEcCtD
Doxorubicin—Vomiting—Pravastatin—atherosclerosis	6.72e-05	0.000692	CcSEcCtD
Doxorubicin—Rash—Pravastatin—atherosclerosis	6.66e-05	0.000686	CcSEcCtD
Doxorubicin—Dermatitis—Pravastatin—atherosclerosis	6.66e-05	0.000685	CcSEcCtD
Doxorubicin—Headache—Pravastatin—atherosclerosis	6.62e-05	0.000681	CcSEcCtD
Doxorubicin—Nausea—Niacin—atherosclerosis	6.38e-05	0.000656	CcSEcCtD
Doxorubicin—Nausea—Pravastatin—atherosclerosis	6.28e-05	0.000646	CcSEcCtD
Doxorubicin—ABCB1—adipose tissue—atherosclerosis	6.09e-05	0.000864	CbGeAlD
Doxorubicin—CYP3A4—liver—atherosclerosis	6.04e-05	0.000856	CbGeAlD
Doxorubicin—CYP2D6—liver—atherosclerosis	5.94e-05	0.000842	CbGeAlD
Doxorubicin—ABCB1—liver—atherosclerosis	4.27e-05	0.000606	CbGeAlD
Doxorubicin—ABCC1—Metabolism—GPX1—atherosclerosis	2.93e-06	2.75e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PPARG—atherosclerosis	2.92e-06	2.74e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—APOA2—atherosclerosis	2.91e-06	2.73e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PLA2G2A—atherosclerosis	2.91e-06	2.73e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ALOX15—atherosclerosis	2.91e-06	2.73e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ALOX5AP—atherosclerosis	2.91e-06	2.73e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—LPL—atherosclerosis	2.9e-06	2.72e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CCL2—atherosclerosis	2.9e-06	2.72e-05	CbGpPWpGaD
Doxorubicin—NOS1—Disease—AKT1—atherosclerosis	2.9e-06	2.72e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PIK3CG—atherosclerosis	2.9e-06	2.72e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—TGFB1—atherosclerosis	2.89e-06	2.71e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—HMOX1—atherosclerosis	2.89e-06	2.71e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ABCG5—atherosclerosis	2.88e-06	2.7e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—INS—atherosclerosis	2.86e-06	2.68e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—IGF1—atherosclerosis	2.85e-06	2.68e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—BGN—atherosclerosis	2.85e-06	2.68e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—CD36—atherosclerosis	2.85e-06	2.67e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—GPX1—atherosclerosis	2.83e-06	2.66e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PTGS2—atherosclerosis	2.83e-06	2.65e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—APOA5—atherosclerosis	2.83e-06	2.65e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—NOS2—atherosclerosis	2.8e-06	2.63e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PPARG—atherosclerosis	2.8e-06	2.62e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—LPA—atherosclerosis	2.78e-06	2.6e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—HMGCR—atherosclerosis	2.77e-06	2.6e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—APOB—atherosclerosis	2.77e-06	2.59e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—CD36—atherosclerosis	2.76e-06	2.59e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—IL6—atherosclerosis	2.75e-06	2.58e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—INS—atherosclerosis	2.74e-06	2.57e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PLA2G1B—atherosclerosis	2.72e-06	2.55e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CXCL8—atherosclerosis	2.72e-06	2.55e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—SERPINE1—atherosclerosis	2.71e-06	2.54e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—MTHFR—atherosclerosis	2.7e-06	2.53e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—PPARA—atherosclerosis	2.69e-06	2.53e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—GSTM1—atherosclerosis	2.69e-06	2.52e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—BGN—atherosclerosis	2.69e-06	2.52e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—APOA5—atherosclerosis	2.66e-06	2.5e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PPARA—atherosclerosis	2.65e-06	2.49e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—LPL—atherosclerosis	2.64e-06	2.48e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—STAT3—atherosclerosis	2.64e-06	2.47e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—ALOX5—atherosclerosis	2.63e-06	2.46e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—ALB—atherosclerosis	2.62e-06	2.46e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—MTHFR—atherosclerosis	2.61e-06	2.45e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—GPX1—atherosclerosis	2.58e-06	2.42e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—AGT—atherosclerosis	2.57e-06	2.41e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—INS—atherosclerosis	2.57e-06	2.41e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PPARA—atherosclerosis	2.57e-06	2.41e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PLA2G1B—atherosclerosis	2.56e-06	2.4e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—AKT1—atherosclerosis	2.54e-06	2.38e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—APOA1—atherosclerosis	2.53e-06	2.37e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—MAPK3—atherosclerosis	2.52e-06	2.36e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—APOE—atherosclerosis	2.52e-06	2.36e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—ALB—atherosclerosis	2.52e-06	2.36e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—CD36—atherosclerosis	2.51e-06	2.35e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—NOS3—atherosclerosis	2.51e-06	2.35e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—CAV1—atherosclerosis	2.49e-06	2.34e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—APOA1—atherosclerosis	2.49e-06	2.33e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—AGT—atherosclerosis	2.48e-06	2.33e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ALOX5—atherosclerosis	2.48e-06	2.32e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—ABCA1—atherosclerosis	2.47e-06	2.31e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—MMP9—atherosclerosis	2.46e-06	2.3e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—TGFB1—atherosclerosis	2.44e-06	2.29e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—APOE—atherosclerosis	2.43e-06	2.28e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—NFKB1—atherosclerosis	2.43e-06	2.28e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—CAV1—atherosclerosis	2.41e-06	2.26e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—APOA1—atherosclerosis	2.41e-06	2.26e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—NOS3—atherosclerosis	2.41e-06	2.26e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ABCG1—atherosclerosis	2.4e-06	2.25e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—MAPK8—atherosclerosis	2.39e-06	2.24e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—MTHFR—atherosclerosis	2.38e-06	2.23e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—IL6—atherosclerosis	2.37e-06	2.22e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—SERPINE1—atherosclerosis	2.36e-06	2.21e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—NAMPT—atherosclerosis	2.36e-06	2.21e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—LIPC—atherosclerosis	2.34e-06	2.19e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PPARA—atherosclerosis	2.33e-06	2.19e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—APOC3—atherosclerosis	2.33e-06	2.18e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—LDLR—atherosclerosis	2.31e-06	2.17e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PTGS2—atherosclerosis	2.3e-06	2.15e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CXCL8—atherosclerosis	2.3e-06	2.15e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PIK3CG—atherosclerosis	2.27e-06	2.13e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—AGT—atherosclerosis	2.26e-06	2.12e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CETP—atherosclerosis	2.26e-06	2.12e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—LCAT—atherosclerosis	2.25e-06	2.11e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—FABP4—atherosclerosis	2.25e-06	2.11e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—NOS3—atherosclerosis	2.25e-06	2.11e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—NAMPT—atherosclerosis	2.22e-06	2.08e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—atherosclerosis	2.22e-06	2.08e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—APOE—atherosclerosis	2.21e-06	2.08e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—APOA4—atherosclerosis	2.21e-06	2.07e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—VEGFA—atherosclerosis	2.21e-06	2.07e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—LIPC—atherosclerosis	2.21e-06	2.07e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PTGS2—atherosclerosis	2.2e-06	2.06e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PIK3CG—atherosclerosis	2.2e-06	2.06e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—CAV1—atherosclerosis	2.19e-06	2.06e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PPARG—atherosclerosis	2.19e-06	2.06e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—APOC3—atherosclerosis	2.19e-06	2.06e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—APOA1—atherosclerosis	2.19e-06	2.05e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—AKT1—atherosclerosis	2.19e-06	2.05e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—STAT3—atherosclerosis	2.18e-06	2.05e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—IL6—atherosclerosis	2.18e-06	2.04e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—LDLR—atherosclerosis	2.18e-06	2.04e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CYP7A1—atherosclerosis	2.17e-06	2.04e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—SCARB1—atherosclerosis	2.16e-06	2.03e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—INS—atherosclerosis	2.15e-06	2.02e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CETP—atherosclerosis	2.13e-06	2e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PPARG—atherosclerosis	2.12e-06	1.99e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—HMOX1—atherosclerosis	2.12e-06	1.99e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—MAPK3—atherosclerosis	2.09e-06	1.96e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—INS—atherosclerosis	2.08e-06	1.95e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—MMP9—atherosclerosis	2.08e-06	1.95e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PTGS2—atherosclerosis	2.06e-06	1.93e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—NFKB1—atherosclerosis	2.05e-06	1.93e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—HMGCR—atherosclerosis	2.04e-06	1.91e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—SCARB1—atherosclerosis	2.04e-06	1.91e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—APOB—atherosclerosis	2.03e-06	1.9e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—TGFB1—atherosclerosis	2.03e-06	1.9e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—MAPK8—atherosclerosis	2.02e-06	1.89e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—AKT1—atherosclerosis	2.01e-06	1.88e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CYP27A1—atherosclerosis	2.01e-06	1.88e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—ALB—atherosclerosis	2e-06	1.88e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PIK3CG—atherosclerosis	2e-06	1.87e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—GSTM1—atherosclerosis	1.97e-06	1.85e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—ALB—atherosclerosis	1.97e-06	1.85e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—LPL—atherosclerosis	1.94e-06	1.82e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PPARG—atherosclerosis	1.93e-06	1.81e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—HMGCR—atherosclerosis	1.92e-06	1.8e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—ALB—atherosclerosis	1.91e-06	1.79e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	1.9e-06	1.78e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—APOA2—atherosclerosis	1.9e-06	1.78e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ALOX15—atherosclerosis	1.9e-06	1.78e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	1.9e-06	1.78e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—INS—atherosclerosis	1.89e-06	1.77e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—GPX1—atherosclerosis	1.89e-06	1.77e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—NOS3—atherosclerosis	1.89e-06	1.77e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ABCG5—atherosclerosis	1.88e-06	1.76e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—VEGFA—atherosclerosis	1.86e-06	1.75e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—STAT3—atherosclerosis	1.85e-06	1.73e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—IL6—atherosclerosis	1.84e-06	1.73e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CD36—atherosclerosis	1.84e-06	1.73e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—NOS3—atherosclerosis	1.82e-06	1.71e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—ABCA1—atherosclerosis	1.82e-06	1.71e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—LPA—atherosclerosis	1.82e-06	1.7e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—MAPK3—atherosclerosis	1.76e-06	1.65e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—BGN—atherosclerosis	1.76e-06	1.65e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—AKT1—atherosclerosis	1.74e-06	1.64e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—MTHFR—atherosclerosis	1.74e-06	1.63e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—APOA5—atherosclerosis	1.74e-06	1.63e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—ALB—atherosclerosis	1.73e-06	1.63e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PTGS2—atherosclerosis	1.72e-06	1.62e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ABCA1—atherosclerosis	1.72e-06	1.61e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—TGFB1—atherosclerosis	1.71e-06	1.6e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PPARA—atherosclerosis	1.71e-06	1.6e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—AKT1—atherosclerosis	1.7e-06	1.59e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—AKT1—atherosclerosis	1.68e-06	1.58e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	1.68e-06	1.57e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PTGS2—atherosclerosis	1.67e-06	1.56e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—NOS3—atherosclerosis	1.66e-06	1.56e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—AGT—atherosclerosis	1.66e-06	1.55e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—APOE—atherosclerosis	1.62e-06	1.52e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ALOX5—atherosclerosis	1.62e-06	1.52e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CAV1—atherosclerosis	1.61e-06	1.51e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—STAT3—atherosclerosis	1.61e-06	1.51e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—APOA1—atherosclerosis	1.6e-06	1.5e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—AKT1—atherosclerosis	1.57e-06	1.47e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—HMOX1—atherosclerosis	1.56e-06	1.46e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—MAPK3—atherosclerosis	1.53e-06	1.44e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—IL6—atherosclerosis	1.53e-06	1.43e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PTGS2—atherosclerosis	1.52e-06	1.42e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—APOB—atherosclerosis	1.5e-06	1.4e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—TGFB1—atherosclerosis	1.49e-06	1.4e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—HMOX1—atherosclerosis	1.47e-06	1.38e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PIK3CG—atherosclerosis	1.47e-06	1.37e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—GSTM1—atherosclerosis	1.46e-06	1.36e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—NAMPT—atherosclerosis	1.45e-06	1.36e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—LIPC—atherosclerosis	1.44e-06	1.35e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—APOC3—atherosclerosis	1.43e-06	1.34e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—LPL—atherosclerosis	1.43e-06	1.34e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—LDLR—atherosclerosis	1.42e-06	1.34e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—AKT1—atherosclerosis	1.42e-06	1.33e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PPARG—atherosclerosis	1.41e-06	1.33e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—APOB—atherosclerosis	1.41e-06	1.32e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—AKT1—atherosclerosis	1.41e-06	1.32e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—GPX1—atherosclerosis	1.39e-06	1.31e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CETP—atherosclerosis	1.39e-06	1.3e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—INS—atherosclerosis	1.39e-06	1.3e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—GSTM1—atherosclerosis	1.37e-06	1.29e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CD36—atherosclerosis	1.36e-06	1.27e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—LPL—atherosclerosis	1.35e-06	1.26e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—SCARB1—atherosclerosis	1.33e-06	1.25e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—GPX1—atherosclerosis	1.31e-06	1.23e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—IL6—atherosclerosis	1.29e-06	1.21e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—MTHFR—atherosclerosis	1.29e-06	1.21e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CD36—atherosclerosis	1.28e-06	1.2e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—ALB—atherosclerosis	1.27e-06	1.19e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PPARA—atherosclerosis	1.26e-06	1.18e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—HMGCR—atherosclerosis	1.26e-06	1.18e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—AGT—atherosclerosis	1.22e-06	1.15e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—NOS3—atherosclerosis	1.22e-06	1.14e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—MTHFR—atherosclerosis	1.21e-06	1.14e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—APOE—atherosclerosis	1.2e-06	1.12e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—AKT1—atherosclerosis	1.19e-06	1.12e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PPARA—atherosclerosis	1.19e-06	1.11e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CAV1—atherosclerosis	1.19e-06	1.11e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—APOA1—atherosclerosis	1.18e-06	1.11e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—AKT1—atherosclerosis	1.15e-06	1.08e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—AGT—atherosclerosis	1.15e-06	1.08e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—APOE—atherosclerosis	1.13e-06	1.06e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—IL6—atherosclerosis	1.12e-06	1.05e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ABCA1—atherosclerosis	1.12e-06	1.05e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CAV1—atherosclerosis	1.12e-06	1.05e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—APOA1—atherosclerosis	1.12e-06	1.05e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PTGS2—atherosclerosis	1.11e-06	1.04e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—AKT1—atherosclerosis	1.11e-06	1.04e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PIK3CG—atherosclerosis	1.08e-06	1.01e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PPARG—atherosclerosis	1.04e-06	9.78e-06	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—AKT1—atherosclerosis	1.04e-06	9.7e-06	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—INS—atherosclerosis	1.02e-06	9.59e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PIK3CG—atherosclerosis	1.02e-06	9.55e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PPARG—atherosclerosis	9.83e-07	9.21e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—INS—atherosclerosis	9.64e-07	9.04e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—HMOX1—atherosclerosis	9.62e-07	9.02e-06	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—ALB—atherosclerosis	9.38e-07	8.79e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—APOB—atherosclerosis	9.22e-07	8.64e-06	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—NOS3—atherosclerosis	8.97e-07	8.41e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GSTM1—atherosclerosis	8.97e-07	8.41e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ALB—atherosclerosis	8.84e-07	8.29e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—LPL—atherosclerosis	8.8e-07	8.25e-06	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—AKT1—atherosclerosis	8.67e-07	8.13e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GPX1—atherosclerosis	8.59e-07	8.05e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—NOS3—atherosclerosis	8.45e-07	7.93e-06	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—AKT1—atherosclerosis	8.38e-07	7.86e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CD36—atherosclerosis	8.36e-07	7.84e-06	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PTGS2—atherosclerosis	8.2e-07	7.69e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—MTHFR—atherosclerosis	7.92e-07	7.43e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PPARA—atherosclerosis	7.77e-07	7.29e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PTGS2—atherosclerosis	7.73e-07	7.25e-06	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—AKT1—atherosclerosis	7.63e-07	7.15e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—AGT—atherosclerosis	7.53e-07	7.06e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—APOE—atherosclerosis	7.38e-07	6.92e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CAV1—atherosclerosis	7.31e-07	6.85e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—APOA1—atherosclerosis	7.29e-07	6.84e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PIK3CG—atherosclerosis	6.66e-07	6.24e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PPARG—atherosclerosis	6.43e-07	6.02e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—INS—atherosclerosis	6.3e-07	5.91e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ALB—atherosclerosis	5.78e-07	5.42e-06	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—AKT1—atherosclerosis	5.59e-07	5.24e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—NOS3—atherosclerosis	5.53e-07	5.18e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PTGS2—atherosclerosis	5.06e-07	4.74e-06	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—AKT1—atherosclerosis	4.12e-07	3.87e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—AKT1—atherosclerosis	3.89e-07	3.64e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—AKT1—atherosclerosis	2.54e-07	2.38e-06	CbGpPWpGaD
